OCCIDENT invests in deep tech start-ups with a focus on spin-offs originating from scientific research, thus having a real impact and enabling concrete solutions for different challenges facing society today. As an owner-managed venture capital investor with offices in Munich and Zug, OCCIDENT supports start-ups in the life sciences and industrial tech sectors from the seed stage onwards, accompanies their portfolio companies over the long term both financially as well as with their extensive experience, and thus enables founding teams to achieve outstanding results. With a strong entrepreneurial mindset, OCCIDENT invests its own money and makes decisions based on sustainable potential for success. Co-operation with the founding teams of their portfolio companies motivates the OCCIDEN team and inspires them every day. They are energized by their passion and drive, and the often very intense exchange spurs them on to tackle challenges together. OCCIDENT’s aim with each and every one of their investments is to make a positive contribution to society in a sustainable way.
31
Total Investments
18
Portfolio Companies
-
Exits
1
Industries
General Information
Industries
Financial Services
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Occident
Recent Investments (31)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series C | •••••• | Oct 2025 | |
| Late Vc | •••••• | Jun 2025 | |
| Series B | •••••• | Mar 2024 | |
| Series B | •••••• | Mar 2024 | |
| Series A | •••••• | Feb 2024 | |
|
|
Seed | •••••• | Jan 2024 |
|
|
Seed Round | •••••• | Jul 2023 |
|
|
Series A | •••••• | Jun 2023 |
|
|
Series D | •••••• | Mar 2023 |
|
|
Series A | •••••• | Sep 2022 |
Latest News
Zürich-based Immitra Bio secures €2.58 million to scale its scalable in-vivo genetic medicine platform
Eu-startups · Jul 22, 2026
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.